e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

144.86 +0.70 (+0.48%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023 ↗

July 06, 2023

Via Benzinga

Expert Ratings for Neurocrine Biosciences ↗

June 30, 2023

Via Benzinga

What 15 Analyst Ratings Have To Say About Neurocrine Biosciences ↗

June 05, 2023

Via Benzinga

Neurocrine Biosciences's Return On Capital Employed Overview ↗

May 08, 2023

Via Benzinga

Neurocrine Biosciences Clocks 35% Revenue Growth In Q1, Misses On Bottom-Line Performance ↗

May 03, 2023

Via Benzinga

Neurocrine Biosciences: Q1 Earnings Insights ↗

May 03, 2023

Via Benzinga

Neurocrine Biosciences's Earnings: A Preview ↗

May 02, 2023

Via Benzinga

What 15 Analyst Ratings Have To Say About Neurocrine Biosciences ↗

April 17, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 ↗

May 04, 2023

Via Benzinga

3 Pharma Stocks That Could See a Surge in Demand in 2023 ↗

April 24, 2023

These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead

Via InvestorPlace

Expert Ratings for Neurocrine Biosciences ↗

March 30, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023 ↗

March 30, 2023

Via Benzinga

Analyst Expectations for Neurocrine Biosciences's Future ↗

March 03, 2023

Via Benzinga

3 Growth Stocks That Could Disrupt the Healthcare Industry ↗

March 13, 2023

These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023 ↗

March 03, 2023

Via Benzinga

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

February 14, 2023

From Sentia Medical Sciences, Inc.

Via GlobeNewswire

Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets ↗

February 06, 2023

Neurocrine also topped fourth-quarter revenue expectations on Monday.

Via Investor's Business Daily

Neurocrine Biosciences Earnings Preview ↗

February 03, 2023

Via Benzinga

Why Voyager Therapeutics Stock Is Sinking This Week ↗

January 20, 2023

Investors are taking profits on this red-hot stock this week.

Via The Motley Fool

Earnings Scheduled For February 6, 2023 ↗

February 06, 2023

Companies Reporting Before The Bell • Cummins (NYSE:CMI) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion.

Via Benzinga

Five Best And Worst Performing Healthcare Stocks In January 2023 ↗

February 05, 2023

After a sub-par performance in 2021, healthcare stocks outperformed the S&P 500 in 2022. As well, 2023 is expected to be another promising year for the sector. Let’s take a look at the five best and...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023 ↗

February 03, 2023

Via Benzinga

Analyst Views Karuna Therapeutics' New Licensing Deal 'As Intriguing' ↗

February 03, 2023

Via Benzinga

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?

January 25, 2023

Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.

Via MarketBeat

7 A-Rated Stocks to Buy for Less Than $25 ↗

January 24, 2023

These seven stocks to buy for less than $25 per share are strong opportunities in today's resilient yet uncertain market.

Via InvestorPlace

Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review ↗

January 13, 2023

Sharp Tesla price cuts and some notable earnings were in focus.

Via Investor's Business Daily

Voyager Therapeutics (VYGR) Stock Gains 18% on Gene Therapy Deal ↗

January 09, 2023

Voyager Therapeutics' lucrative arrangement with a fellow biotech business is putting VYGR stock traders in a buying mood today.

Via InvestorPlace

Neurocrine Biosciences, Voyager Therapeutics Collaborate For Neurological-Focused Gene Therapies ↗

January 09, 2023

Via Benzinga

Have A Look At William Blair's Top Biotech Picks For 2023 ↗

December 25, 2022

William Blair & Company's report outlined some key themes and significant trends to monitor while entering 2023, providing its top stock ideas for the upcoming 12-month period.

Via Benzinga

Dow Jones Giant UnitedHealth Among 5 Resilient Stocks In Sickly Market Rally ↗

December 17, 2022

UnitedHealth is among medical stocks holding key support.

Via Investor's Business Daily

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy